{"id":"W4403568842","doi":"10.1016/j.htct.2024.09.865","title":"LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES","year":2024,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Subgroup analysis; Refractory (planetary science); Multiple myeloma; Internal medicine; Term (time); Oncology; Meta-analysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004467517,0.001018493,0.003374529,0.0005111848,0.000913418,0.001624375,0.0006192287,0.001249878,0.002676318],"category_scores_gemma":[0.003097158,0.0004317488,0.004650163,0.000737735,0.000387316,0.001368177,0.0007944869,0.002881984,0.0005807998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007708017,"about_ca_system_score_gemma":0.0009940891,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009521187,"about_ca_topic_score_gemma":0.002816822,"domain_scores_codex":[0.9984812,0.0005064702,0.0002064775,0.0003105062,0.0001946834,0.000300578],"domain_scores_gemma":[0.9972869,0.0005818911,0.0006730052,0.0004515616,0.000322936,0.0006837036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7504972,0.003364487,0.1329075,0.001535186,0.02373899,0.0007209534,0.000372308,0.002412235,0.01011045,0.0002650308,0.0104376,0.06363808],"study_design_scores_gemma":[0.2204338,0.1252332,0.5925568,0.0004866884,0.03464334,0.00151873,0.0005162921,0.002720615,0.003423802,0.001454178,0.01679744,0.0002149688],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796025,0.00821225,0.0008046197,0.0005927239,0.0001967284,0.001071612,0.006585959,0.00005956259,0.002874006],"genre_scores_gemma":[0.9788914,0.001329956,0.0004676014,0.001370637,0.0003493493,0.001030402,0.01474657,0.00003380925,0.001780318],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004467517,"threshold_uncertainty_score":0.02362674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01566741291213274,"score_gpt":0.2839526485226636,"score_spread":0.2682852356105309,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}